Neoplasms

Symptoms and General Pathology

All Conditions

Skin and Connective Tissue Diseases

Rare Diseases

Neoplasm Metastasis

Melanoma

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Skin Diseases

Neoplastic Processes

Neuroendocrine Tumor

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Cisplatin

Dacarbazine

Vindesine

Antineoplastic Agents, Alkylating

Alkylating Agents

Tubulin Modulators

Antimitotic Agents

Cisplatin, Vindesine, Dacarbazine (drugs)

Jens Ulrich, MD

Dirk Schadendorf, MD

Claus Garbe, MD

Konstanze Spieth, MD

Peter Mohr, MD

Michael Tronnier, MD

Wolfgang Tilgen, MD

Dorothea Tadler, MD

Vassiliki Bekou, MD

Axel Hauschild, MD

Sven Krengel, MD

Ruthild Linse, MD

Yvonne Kellner, MD

Martin Kaatz, MD

Uwe Trefzer, MD

Maja Hofmann, MD

Peter Kohl, MD

The purpose of this multicenter study is to examine whether the proposed randomized treatment regime results in a significantly longer survival time and higher quality of life than any additionally applied multiple chemotherapy according to the CVD- scheme. So far neither established treatment regimes nor reliable data exist for the second-line chemotherapy of metastatic malignant melanoma. Patients are therefore mostly treated with single or multiple chemotherapeutics or/and immunomodulatory therapeutics. These regimes however imply often not only a higher toxicity but show rarely a response rate higher than 10%.

Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma

Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy (CVD-Protocol) in the Second-Line Therapy of Distant Metastasized Malignant Melanoma

Dermatologic Cooperative Oncology Group

Spots Global Cancer Trial Database for cisplatin, vindesine, dacarbazine (drugs)